Assertio Therapeutics Stock Analysis
ASRT Stock | USD 0.97 0.02 2.11% |
Assertio Therapeutics is overvalued with Real Value of 0.86 and Target Price of 6.75. The main objective of Assertio Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Assertio Therapeutics is worth, separate from its market price. There are two main types of Assertio Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Assertio Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Assertio Therapeutics is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Assertio Stock trading window is adjusted to America/New York timezone.
Assertio |
Assertio Stock Analysis Notes
About 38.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.7. Some equities with similar Price to Book (P/B) outperform the market in the long run. Assertio Therapeutics has Price/Earnings To Growth (PEG) ratio of 1.19. The entity recorded a loss per share of 4.94. The firm had not issued any dividends in recent years. Assertio Therapeutics had 1:4 split on the 18th of May 2021. Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois. Assertio Holdings operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. For more info on Assertio Therapeutics please contact Brendan OGrady at 224 419 7106 or go to https://www.assertiotx.com.Assertio Therapeutics Quarterly Total Revenue |
|
Assertio Therapeutics Investment Alerts
Assertio Therapeutics generated a negative expected return over the last 90 days | |
Assertio Therapeutics has some characteristics of a very speculative penny stock | |
Assertio Therapeutics has high historical volatility and very poor performance | |
Assertio Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
The company reported the previous year's revenue of 152.07 M. Net Loss for the year was (331.94 M) with profit before overhead, payroll, taxes, and interest of 138.29 M. | |
Latest headline from thelincolnianonline.com: Assertio Holdings, Inc. Director Heather L. Mason Buys 75,000 Shares |
Assertio Therapeutics Upcoming and Recent Events
13th of March 2024 Upcoming Quarterly Report | View | |
14th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
13th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Assertio Largest EPS Surprises
Earnings surprises can significantly impact Assertio Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-11-11 | 2024-09-30 | -0.04 | -0.03 | 0.01 | 25 | ||
2024-08-07 | 2024-06-30 | -0.03 | -0.04 | -0.01 | 33 | ||
2022-11-08 | 2022-09-30 | 0.07 | 0.08 | 0.01 | 14 |
Assertio Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Two Sigma Investments Llc | 2024-06-30 | 959.9 K | Amvescap Plc. | 2024-06-30 | 564.1 K | Susquehanna International Group, Llp | 2024-06-30 | 490.3 K | Bridgeway Capital Management, Llc | 2024-06-30 | 409.9 K | Empowered Funds, Llc | 2024-06-30 | 409.9 K | Jane Street Group Llc | 2024-06-30 | 406.6 K | Perritt Capital Management Inc. | 2024-09-30 | 390.1 K | Bank Of New York Mellon Corp | 2024-06-30 | 351.7 K | State Street Corp | 2024-06-30 | 339.3 K | Nantahala Capital Management, Llc | 2024-06-30 | 18.5 M | Vanguard Group Inc | 2024-09-30 | 4.5 M |
Assertio Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 81.8 M.Assertio Profitablity
The company has Profit Margin (PM) of (0.54) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.09) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.09.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (1.90) | (1.80) | |
Return On Capital Employed | (1.26) | (1.20) | |
Return On Assets | (1.16) | (1.10) | |
Return On Equity | (2.41) | (2.29) |
Management Efficiency
Assertio Therapeutics has return on total asset (ROA) of (0.0144) % which means that it has lost $0.0144 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4236) %, meaning that it created substantial loss on money invested by shareholders. Assertio Therapeutics' management efficiency ratios could be used to measure how well Assertio Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -1.8 in 2024. Return On Capital Employed is likely to gain to -1.2 in 2024. Liabilities And Stockholders Equity is likely to gain to about 336.5 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 72.3 M in 2024.Last Reported | Projected for Next Year | ||
Book Value Per Share | 1.94 | 1.85 | |
Tangible Book Value Per Share | 0.38 | 0.39 | |
Enterprise Value Over EBITDA | (0.20) | (0.19) | |
Price Book Value Ratio | 0.55 | 0.52 | |
Enterprise Value Multiple | (0.20) | (0.19) | |
Price Fair Value | 0.55 | 0.52 | |
Enterprise Value | 1.5 B | 1.6 B |
The strategic initiatives led by Assertio Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Operating Margin (0.09) | Profit Margin (0.54) | Beta 0.835 | Return On Assets (0.01) | Return On Equity (0.42) |
Technical Drivers
As of the 22nd of November, Assertio Therapeutics shows the Risk Adjusted Performance of (0.05), mean deviation of 3.24, and Standard Deviation of 4.53. Assertio Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Assertio Therapeutics Price Movement Analysis
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Assertio Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Assertio Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Assertio Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Assertio Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Assertio Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Assertio Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Assertio Therapeutics Outstanding Bonds
Assertio Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Assertio Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Assertio bonds can be classified according to their maturity, which is the date when Assertio Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
ASSOCIATED BANC P Corp BondUS045487AB12 | View |
Assertio Therapeutics Predictive Daily Indicators
Assertio Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Assertio Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Assertio Therapeutics Forecast Models
Assertio Therapeutics' time-series forecasting models are one of many Assertio Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Assertio Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Assertio Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Assertio Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Assertio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Assertio Therapeutics. By using and applying Assertio Stock analysis, traders can create a robust methodology for identifying Assertio entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (1.67) | (1.75) | |
Operating Profit Margin | (1.60) | (1.68) | |
Net Loss | (2.18) | (2.29) | |
Gross Profit Margin | 0.82 | 1.32 |
Current Assertio Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Assertio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Assertio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
6.75 | Strong Buy | 4 | Odds |
Most Assertio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Assertio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Assertio Therapeutics, talking to its executives and customers, or listening to Assertio conference calls.
Assertio Stock Analysis Indicators
Assertio Therapeutics stock analysis indicators help investors evaluate how Assertio Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Assertio Therapeutics shares will generate the highest return on investment. By understating and applying Assertio Therapeutics stock analysis, traders can identify Assertio Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 64.9 M | |
Long Term Debt | 38.2 M | |
Common Stock Shares Outstanding | 71 M | |
Total Stockholder Equity | 138 M | |
Tax Provision | 77.9 M | |
Quarterly Earnings Growth Y O Y | -0.188 | |
Property Plant And Equipment Net | 2 M | |
Cash And Short Term Investments | 73.4 M | |
Cash | 73.4 M | |
Accounts Payable | 13.4 M | |
Net Debt | -32.5 M | |
50 Day M A | 1.1284 | |
Total Current Liabilities | 93.4 M | |
Other Operating Expenses | 395.6 M | |
Non Current Assets Total | 115.4 M | |
Forward Price Earnings | 11.8765 | |
Non Currrent Assets Other | 2 M | |
Stock Based Compensation | 9.2 M |
Additional Tools for Assertio Stock Analysis
When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.